Keros Therapeutics drops another Phase II cibotercept trial

15 January 2025

US clinical-stage pharma Keros Therapeutics (Nasdaq: KROS) today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase II clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH), including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events.

Keros shares slumped 17.4% to $10.31 by late morning trading on the development.

On December 12, 2024, the company announced that it had voluntarily halted the 3.0 mg/kg and 4.5 mg/kg treatment based on the observation of pericardial effusions at those dose levels. That news caused a 73% slump in its share price.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical